A new RP-HPLC method for simultaneous estimation of nebivolol hydrochloride and hydrochlorthiazide in dosage forms

Abstract

A new RP-HPLC method has been developed for the simultaneous estimation of nebivolol hydrochloride and hydrochlorothiazide in pharmaceutical dosage forms, using ultra violet (UV) detector. Elution was carried out using a mobile phase consisting of acetonitrile and potassium dihydrogen phosphate buffer (pH 3.2 ± 0.1) in the ratio of 50:50 v/v and s ow rate was set on 1.2 ml/min at 282 nm. The retention time for hydrochlorothiazide and nebivolol hydrochloride was found 3.57 and 6.66 mins, respectively. The method was found to be linear in the range of 8–32 μg/ml and 20–80 μg/ml for nebivolol hydrochloride and hydrochlorothiazide, respectively. In the linearity study, regression equation and coefÞ cient of correlation for nebivolol hydrochloride and hydrochlorothiazide were found to be: y = 284761x + 215452, r = 0.9995; and y = 698395+105272, r = 0.9998, respectively. Key words: HPLC, Hydrochlorthiazide, method validation, nebivolol hydrochloride.